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Abstract OBJECTIVES: Previous studies have reported that exogenous salsolinol might 
contribute to myenteric cell death and altered gastrointestinal motility. Because 
the entire gut mucosal, entero-endocrine and motor functions are integrated 
by the enteric nervous system, the aim of the present study was to investigate if 
prolonged intraperitoneal salsolinol administration alters basic metabolism and 
nutritional parameters in adult Wistar rats fed normal or high-fat diets.
METHODS: Male Wistar rats were subjected to continuous intraperitoneal low 
dosing of salsolinol with ALZET osmotic mini-pumps for 2 or 4 weeks and fed 
either a normal or high-fat diet. Appropriate groups served as the controls. Nutri-
tional status (food intake, body weight, and epididymal fat pads weight), residual 
solid food in the stomach and biochemical parameters (GIP, GLP-1, CRF, glucose, 
TG, LDL, HDL) were assessed.
RESULTS: Prolonged salsolinol treatment significantly reduced total body mass 
and adipose tissue accumulation. The effects were more pronounced in the 
salsolinol-treated rats fed a high-fat diet. In salsolinol-treated rats, serum post-
prandial GIP levels were elevated, and serum postprandial GLP-1 levels were 
lower compared with the appropriate controls. 
CONCLUSIONS: Salsolinol might influence the regulatory mechanisms of body 
weight and epididymal fat pad accumulation through neurohormonal pathways.
Abbreviations:
aVTA  - anterior part of ventral tegmental area
CRF  - corticotropin-releasing factor
1,2-DMDHIQ+  - 1,2-dimethyl-6,7-dihydroxyisoquinolinium ion
GIP  - glucose-dependent insulinotropic polypeptide
GLP-1  - glucagon-like peptide-1
HDL  - high-density lipoproteins
i.p.  - intraperitoneal 
LDL  - low-density lipoproteins
MPTP  - 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
NAc  - nucleus accumbens
pVTA  - posterior part of ventral tegmental area
Salsolinol  - 1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline
TG - triglicerydes
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INTRODUCTION
Salsolinol (1-methyl-6,7-dihydroxy-1,2,3,4-tetra-
hydroisoquinoline) is an adduct of dopamine and 
acetaldehyde and belongs to a family of tetrahydroiso-
quinolines that are widespread in nature (McNaught et 
al. 1998; Rommelspacher & Susilo 1985). Salsolinol is 
believed to act as an inhibitor of tyrosine hydroxylase 
and monoaminooxydase type A (Heikkila et al. 1971, 
Storch et al. 2000). It might regulate the function of 
catecholaminergic neurons (especially dopaminergic) 
through its specific binding sites (Naoi et al. 2004) and 
may also act at the level of sympathetic ganglia (Mravec 
et al. 2004). Moreover, it was postulated that salsolinol 
might be a selective and potent stimulator of prolactin 
secretion without affecting the secretion of other pitu-
itary hormones (Homicskó et al. 2003; Tóth et al. 2002).
The chemical structure of salsolinol resembles the 
well-recognised and studied exogenous neurotoxin 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
and is able to form 1,2-dimethyl-6,7-dihydroxyiso-
quinolinium ions (1,2-DMDHIQ+) analogous to 
highly neurotoxic 1-methyl-4-phenylpyridinium ions 
(Maruyama et al. 1997; Naoi et al. 1989; 1994). Możdżeń 
et al. (2015) suggested that salsolinol can exhibit oppos-
ing biological actions depending on its concentration, 
either neuroprotective or pro-apoptotic. Thus, pro-
longed exposure to its high concentration might indeed 
cause apoptotic nerve cell death and could be one of 
the aetiological factors of neurodegenerative disease. 
It was previously reported that Parkinsonian patients 
treated with L-DOPA and chronic alcoholics showed 
significant elevations in the concentration of salsolinol 
in their cerebrospinal fluid and urine (Cohen & Collins 
1970; Collins et al. 1979; Moser & Kompf 1992; Sandler 
et al. 1973), whereas a low concentration of salsolinol 
was detected in normal human cerebrospinal fluid 
(Moser & Kompf 1992), brain and urine (Dostert et 
al. 1989; Sjöquist et al. 1981). However, this difference 
could be a result of its impaired unidentified metabolic 
routes instead of its direct involvement in the process of 
neurodegeneration. It is unknown whether the neuro-
toxic effect of salsolinol in the brain is solely associated 
with dopaminergic structures, and it is still debatable 
and inconclusive whether salsolinol is able to cross the 
blood–brain barrier. Furthermore, salsolinol has been 
detected in various food products, such as alcohol bev-
erages, cheese and bananas (Duncan et al. 1982; 1984; 
Riggin et al. 1976), but its influence on peripheral neu-
rotransmission and metabolism is poorly understood 
and addressed in the literature. 
Recently, we reported that exogenous salsolinol 
induced myenteric neuronal cell (the inhibitory motor 
neurons) death (Kurnik et al. 2015), which might con-
tribute to altered gastrointestinal motility (Banach 
et al. 2005; 2006). Because the entire gut mucosal, 
entero-endocrine and motor functions are integrated 
by the enteric nervous system, the aim of the present 
study was to investigate whether and how prolonged 
intraperitoneal salsolinol administration alters basic 
metabolism and body composition in adult Wistar rats 
fed normal or high-fat diets. We decided to evaluate 
nutritional parameters (body weight gain and epididy-
mal fat pads weight), residual solid food in the stomach 
and biochemical parameters corresponding to incretins 
produced in the small intestine, including postprandial 
serum levels of glucose-dependent insulinotropic poly-
peptide (GIP) and glucagon-like peptide-1 (GLP-1), 
corticotropin-releasing factor (CRF) postprandial glu-
cose, triglycerides (TG), and LDL and HDL (low- and 
high density lipoproteins, respectively), after salsolinol 
administration to address our question. 
Fig. 1. The experimental design. S1, SF1 – 2 weeks of salsolinol i.p. administration in rats fed a standard or high-fat diet, respectively; S2, 
SF2 – 4 weeks of salsolinol i.p. administration in rats fed a standard or high-fat diet, respectively; C1, CF1 – control rats fed a standard or 
high-fat diet for 2 weeks, respectively; C2, CF2 – control rats fed a standard or high-fat diet for 4 weeks, respectively.
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MATERIAL AND METHODS
Animal housing, diet and surgery
Adult male Wistar rats (n=48) were housed in individ-
ual transparent cages allowing for visual contact, with 
food and water provided ad libitum, temperature main-
tained at 23±2 °C and under a 12:12 h dark/light cycle. 
During the experiment, rats were fed either a standard 
diet (caloric distribution of the diet: protein 25%, fat 8%, 
carbohydrates 67%, metabolizable energy 2.86 kcal/g, 
Labofeed B, Kcynia, Poland) or an obesity-inducing 
high-fat diet (caloric distribution of the diet: protein 
25.1%, fat 38.8%, carbohydrates 36.1%, metabolisable 
energy 4.34 kcal/g; Perform, Bento Kronen Products, 
Belgium). Rats were either subjected to continuous 
dosing of salsolinol or used as controls. Salsolinol (sal-
solinol hydrochloride, Sigma, USA) at a total dose of 
200 mg/kg was dissolved in 200 μL of 0.9% NaCl and 
delivered using ALZET osmotic mini-pumps (Durect, 
USA) implanted i.p. Control groups were implanted 
with ALZET osmotic mini-pumps filled with 0.9% 
NaCl. Rats were starved for 12 hours, and mini-pumps 
were implanted under general anaesthesia induced with 
sodium pentobarbital given i.p. at a dose of 0.25 mg/kg 
(Vetbutal, Biowet, Poland). The Jagiellonian University 
Bioethical Committee approved the experiment (ethi-
cal approval number – 67/2009).
Thus, prior to pump implantation, rats were ran-
domly divided into the following experimental groups 
(n=6 rats in each group): (1) rats subjected to continu-
ous dosing of salsolinol for two weeks (ALZET delivery 
rate 0.5 μL/h and fed a standard diet throughout the 
entire experimental period (S1 group); (2) rats sub-
jected to continuous dosing of salsolinol for two weeks 
(ALZET delivery rate 0.5 μL/h) and fed a high-fat diet 
throughout the experiment (SF1 group); (3) rats sub-
jected to continuous dosing of salsolinol for four weeks 
(ALZET delivery rate 0.25 μL/h) and fed a standard diet 
throughout the experiment (S2 group); (4) rats sub-
jected to continuous dosing of salsolinol for four weeks 
(ALZET delivery rate 0.25 μL/h) and fed a high-fat diet 
throughout the experiment (SF2 group); (5) a control 
group fed a standard diet for two weeks (C1 group); (6) 
a control group fed a high-fat diet for two weeks (CF1 
group); (7) a control group fed a standard diet for four 
weeks (C2 group); (8) a control group fed a high fat-
diet for four weeks (CF2 group).
Nutritional status and biochemical determinations
The general health status and motor function of the 
experimental animals were evaluated daily during han-
dling and by observing their in-cage behaviour. Food 
intake (g) and body weight (g) were measured each 
morning during the study. Daily and total food intake 
and daily and total weight gain were calculated. The 
feed efficiency ratio was calculated according to the 
following equation: [body weight gain (g) /total food 
intake (g)] × 100.
At the end of the experiment (either day 15 or day 
29), following 12 h overnight fasting, the rats were 
allowed free access to pre-weighed food for sixty min-
utes. Thirty minutes later, the animals were euthanized 
via decapitation (between 9 and 11 a.m.) and their 
stomachs, epididymal fat pads and blood samples were 
collected.
Each stomach was excised and weighed. The amount 
of food in the stomach was calculated as the difference 
between the total weight of the stomach with its con-
tents and the weight of the stomach after the contents 
were removed (adapted from a method described in 
Greene et al. 2009). The food pellets were weighed 
before and after the feeding period to determine the 
amount consumed by each rat and adjusted to the body 
mass of rats (mg/g of body weight). The residual solid 
food in the stomach after 90 minutes was determined 
according to the following equation: residual solid food 
in the stomach =[dried gastric content (g) / food intake 
(g)] × 100.
Both epididymal fat pads, located between the cauda 
epididymis and the distal extremity of the testis, were 
dissected from each rat and weighted (Bugajski et al. 
2007; Gil at al. 2013). The epididymal fat pad/total 
body weight gain ratio was calculated by dividing the 
weight of the fat pads (g) by the total body weight gain 
(g) and expressed as percentage (%) values. The epi-
didymal fat pad weight over the total food intake ratio 
was calculated by dividing the weight of the fat pads (g) 
by the total food intake (g) and expressed as per mille 
(‰) values.
Blood samples were collected from the jugular ves-
sels in plastic tubes and incubated at least 30 minutes 
at 4 °C to induce clot formation. After centrifugation 
at 1500 ×g for 20 min at 4 °C (Megafuge 1.0R, Heraeus 
Instruments, Germany), serum samples were collected 
and kept frozen at –80 °C until further analysis. Serum 
postprandial levels of GIP, GLP-1 and CRF were assayed 
by quantitative ELISA kits (Phoenix Pharmaceuticals, 
USA) according to the manufacturer’s instructions. 
Serum levels of postprandial glucose, TG, LDL and 
HDL were measured using a chemistry immune-anal-
yser (Olympus AU600, USA). All measurements were 
performed in duplicate.
Statistical analysis
Results were analysed (GraphPad Prism 7.0a, USA) 
using a one-way analysis of variance (ANOVA) fol-
lowed by a post hoc Tukey’s test and are expressed as 
the mean±standard deviation (SD). Statistical signifi-
cance was set at p<0.05. 
RESULTS
Food intake, body weight and epididymal fat pad weight 
None of the salsolinol-treated or control rats died or 
showed any visible disturbances of gross motor func-
tion. There were no significant differences in the mean 
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daily food intake (g) between the salsolinol-treated 
groups and their controls, except for SF2 = 30.66±2.59 
vs. CF2 = 36.38±1.72 (p=0.0011). In addition, there 
were no significant differences in the mean daily energy 
intake (kcal) between the salsolinol-treated groups and 
their controls, except for SF2 = 66.53±5.63 vs. CF2 = 
78.93±3.73 (p=0.028) (Figure 2A). However, salsolinol 
treatment led to significantly reduced body weight by 
the end of the experiment (data not shown). The mean 
daily body weight gain (g) was lower in all salsolinol-
treated rats: S1 = 4.221±0.48 vs. C1 = 5.828±0.21 
(p=0.077); SF1 = 5.061±1.30 vs. CF1 = 7.000±0.997 
(p=0.047); S2 = 3.512±1.13 vs. C2 = 4.299±0.72 
(p=0.523); and SF2 = 3.485±1.03 vs. CF2 = 5.777±0.49 
(p=0.011) (Figure 2B). The mean feed efficiency ratio 
(%) was significantly lower in the salsolinol-treated 
animals fed a high-fat diet: SF1 vs. CF1 (p=0.004) and 
SF2 vs. CF2 (p=0.004) (Figure 2C). The mean feed effi-
ciency ratio (%) was also significantly different for S1 
vs. SF1 (p=0.0001), S2 vs. SF2 (p=0.009), C1 vs. CF1 
(p<0.0001) and C2 vs. CF2 (p<0.0001) (Figure 2C).
The mean epididymal fat pad weight over the total 
food intake ratio (‰) was significantly lower in SF1 
compared with CF1 (p=0.032) and in SF2 compared 
with CF2 (p=0.0007) salsolinol-treated rats (Figure 
2D). The mean epididymal fat pad weight over the 
total weight gain ratio (%) was not significantly dif-
ferent in the salsolinol-treated rats compared with 
the corresponding control groups: S1 = 5.43±0.66 
vs. C1 = 4.584±0.60 (p=0.32), SF1 = 6.098±1.64 vs. 
CF1 = 5.263±0.80 (p=0.53), S2 = 3.295±0.67 vs. C2 = 
3.804±0.37 (p=0.40), and SF2 = 5.047±0.34 vs. CF2 = 
4.793±0.33 (p=0.53). There were no significant differ-
ences between rats fed a normal diet and a high-fat diet 
for both salsolinol-treated and control animals, except 
for S2 vs. SF2 (p=0.012).
Fig. 2. (A) The mean daily food intake (kcal); (B) the mean daily body weight gain (g); (C) the mean feed efficiency ratio (%); (D) the mean 
epididymal fat pad (EFP) weight over the total food intake ratio (‰). Statistical significance: * p< 0.05, ** p< 0.01, *** p< 0.001. S1, 
SF1 – 2 weeks of salsolinol i.p. administration in rats fed a standard or high-fat diet, respectively; S2, SF2 – 4 weeks of salsolinol i.p. 
administration in rats fed a standard or high-fat diet, respectively; C1, CF1 – control rats fed a standard or high-fat diet for 2 weeks, 
respectively; C2, CF2 – control rats fed a standard or high-fat diet for 4 weeks, respectively.
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Residual solid food in the stomach
The mean amount of food consumed within the 
one-hour testing period (mg/g of body weight) was 
not significantly different in the salsolinol-treated 
rats compared with the appropriate control groups: 
S1 = 16.4±3.5 vs. C1 = 19.57±2.49 (p=0.97), SF1  = 
20.05±5.03 vs. CF1 = 19.46±3.10 (p=0.99), S2 = 
14.77±6.99 vs. C2 = 15.41±2.23 (p=0.99), and SF2 = 
15.78±8.06 vs. CF2 = 7.89±1.83 (p=0.25). The mean 
residual solid food in the stomach (%) was significantly 
higher in the S1 group = 80.2±6.0 compared with the 
C1 group = 68.4±6.1 (p=0.033). However, there were no 
significant differences in the mean residual solid food 
among the other groups: SF1 = 76.1±11.0 vs. CF1  = 
71.3±2.8 (p=0.99), S2 = 81.2±4.4 vs. C2 = 73.6±6.8 
(p=0.91), and SF2 = 78.6±17.5 vs. CF2 = 69.1±6.7 
(p=0.79).
Biochemical analyses
The mean postprandial serum GIP levels (ng/ml) were 
elevated in salsolinol-treated rats, especially in S2 = 
0.4194±0.06 vs. C2 = 0.042±0.02 (p=0.0008), excluding 
S1 = 0.0225±0.001 compared with C1 = 0.3206±0.12 
(p=0.0047) (Figure 3A). The mean postprandial serum 
GLP-1 levels (ng/ml) were lower in the salsolinol-
treated rats compared with controls, especially for S1 
= 0.01275±0.012 vs. C1 = 0.03738±0.016 (p=0.0148). 
There were no significant differences between rats fed 
normal and high-fat diets among both the salsolinol-
treated and control animals (Figure 3B). The mean 
serum CRF levels (ng/ml) were comparable in the 
salsolinol-treated rats and their respective controls: 
S1 = 0.09888±0.054 vs. C1 = 0.08783±0.068 (p>0.99), 
S2 = 0.07388±0.010 vs. C2 = 0.1505±0.129 (p=0.75), 
SF1 = 0.1139±0.032 vs. CF1 = 01273±0.102 (p>0.99), 
Fig. 3. (A) The mean postprandial GIP levels (ng/ml); (B) the mean postprandial GLP-1 levels (ng/ml); (C) the mean postprandial LDL over 
HDL ratio; (D) the mean postprandial TG over HDL ratio. Statistical significance: * p< 0.05, *** p< 0.001. S1, SF1 – 2 weeks of salsolinol i.p. 
administration in rats fed a standard or high-fat diet, respectively; S2, SF2 – 4 weeks of salsolinol i.p. administration in rats fed a standard 
or high-fat diet, respectively; C1, CF1 – control rats fed a standard or high-fat diet for 2 weeks, respectively; C2, CF2 – control rats fed a 
standard or high-fat diet for 4 weeks, respectively.
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and SF2 = 0.1260±0.045 vs. CF2 = 0.1280±0.023 
(p>0.99). In addition, there were no differences between 
rats fed normal and high-fat diets among both the sal-
solinol-treated and control rats.
The mean postprandial serum glucose levels (mg/
dl) were not statistically different between the sal-
solinol-treated and control rats: S1 = 134.6±15.0 vs. 
C1 = 122.1±28.7 (p=0.79), S2 = 131.9±11.9 vs. C2 
= 119.7±14.9 (p=0.76), SF1 = 117.4±7.7 vs. CF1 = 
107.1±3.2 (p=0.98), and SF2 = 124.6±8.4 vs. CF2 = 
126.3±10.6 (p>0.99). There were no significant differ-
ences between rats fed normal and high-fat diets among 
both salsolinol-treated and control rats.
The mean postprandial serum levels of both LDL 
and HDL (mmol/l) were not significantly different 
between the salsolinol-treated rats and the appropriate 
control rats. However, the mean LDL over HDL ratio 
was increased in all salsolinol-treated rats compared 
with their controls, especially in S1 = 1.394±0.47 com-
pared with C1 = 0.525±0.51 (p=0.021) (Figure 3C). The 
mean postprandial serum TG levels (mmol/l) were not 
significantly different between the salsolinol-treated 
rats and the appropriate control rats, while the mean 
TG over HDL ratio was slightly increased in all salsoli-
nol-treated rats compared with their controls, although 
this increase was not significant (Figure 3D). 
DISCUSSION
Salsolinol attracted considerate attention in the 1980s 
because of its possible involvement in the etiopathogen-
esis of Parkinson’s disease. Salsolinol can be formed in 
vivo by non-enzymatic Pictet–Spengler condensation 
of dopamine and acetaldehyde, leading to the racemic 
mixture, or by enantioselective formation of (R)-salso-
linol by the enzyme (R)-salsolinol synthase (Naoi et al. 
1996), although the exact site of biosynthesis remains 
unknown. Another important question that has been 
thoroughly explored is its metabolism. In the brain, 
salsolinol metabolism occurs through N-methylation 
and oxidation (Maruyama et al. 1992). The distribution 
of the N-methylated and oxidised derivatives seems to 
follow a specific pattern in the human nigro-striatal 
pathway (Maruyama et al. 1997), which might suggest 
that these derivatives may be involved in the function of 
dopamine neurons under physiological and/or patho-
logical conditions. Primarily neurotoxic effects have 
been attributed to these metabolites (Maruyama et al. 
1992; Naoi et al. 2004), although they might also possess 
neuroprotective properties depending on their concen-
trations (Maruyama et al. 1995; Możdżeń et al. 2015).
Our selected dosage regimen was based on a litera-
ture review (Table 1) and unpublished data from our 
department. We hypothesized that intraperitoneal 
administration of a low dose of salsolinol hydrochlo-
ride (total dose of 200 mg/kg) using ALZET osmotic 
mini-pumps for two (approximately 14 mg/kg salso-
linol daily) or four (approximately 7 mg/kg salsolinol 
daily) weeks would be optimal. The exposure of the 
enteric nervous system would be constant and repeat-
able and would eventually cause mild but stable changes 
within the gut wall. The intraperitoneal administration 
route is used for experimental purposes to deliver drugs 
to small laboratory animals to achieve successful out-
comes due to its accuracy, reliability, and convenient 
delivery, which yields reproducible results rendered 
by a large absorbing surface area. The majority of the 
drug is absorbed by the veins of the mesentery and then 
gathered into the portal vein of the liver, which is simi-
lar to an oral gavage. However, continuous i.p. adminis-
tration with an osmotic mini-pump recreates a disease 
state much better than an i.p. injection and causes less 
acute toxicity and less animal distress (Alvarez-Fisher et 
al. 2008; Fornai et al. 2005).
Dosage and route of administration of salsolinol, the 
initial body weights of male Wistar rats and the authors 
of original articles published since the year 2000 based 
on a PubMed database search (“salsolinol and Wistar 
rats and English”).
The primary finding of our experiment is that pro-
longed salsolinol treatment decreased body weight gain 
and adipose tissue accumulation in Wistar rats. The 
effect was more pronounced in salsolinol-treated rats 
fed a high-fat diet. There were no significant differ-
ences between C1 and CF1 or between C2 and CF2, but 
clearly two to four weeks were not sufficient to develop 
obesity in control rats, which is in agreement with pre-
vious experiments (Gil et al. 2013). Prolonged salsolinol 
treatment decreased the feed efficiency ratio despite the 
same genotype, sex, age, and thermal environment of 
the animals in our experiment. The decreased feed effi-
ciency ratio was associated with decreased epididymal 
fat pad weight over total food intake ratio in salsolinol-
treated rats fed a high-fat diet, especially after four 
weeks of treatment. Therefore, the questions arise as 
to whether i.p. administered salsolinol is metabolised 
and whether our results are mediated peripherally or 
centrally. We previously reported that salsolinol was not 
detected (the limit of detection was set at 0.86 ng/l) in 
serum samples in a similar experimental model, which 
suggests that salsolinol did not reach the systemic blood 
(Kurnik et al. 2012). However, the blood samples were 
collected 24 h after the last delivery, and other related 
metabolites were not measured. It was demonstrated 
that salsolinol competitively inhibited the activity of 
debrisoquine 4-monooxygenase (CYP2D1) and parkin-
sonism-related psychotropic drugs, the molecular struc-
tures of which may correspond not only to the active 
site of CYP2D1 but also to dopamine receptors (Iwa-
hashi et al. 1993). Lee et al. (2010) demonstrated that 
a single administration of salsolinol (10 μg) by gavage 
resulted in a significant elevation of rat (Sprague-Daw-
ley) plasma salsolinol levels, which sharply declined to 
near basal levels by 14 hours. The mean plasma concen-
trations of (S)- and (R)-salsolinol at 1 hour after admin-
istration were 650±46 and 614±42 pg/ml, respectively. 
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The mean basal (S)- and (R)-salsolinol levels were 
11±4 and 10±1 pg/ml, respectively. A single intake of 
3 g banana (corresponding to 75 μg of salsolinol) also 
increased the plasma salsolinol concentration. Despite 
the increases observed in plasma salsolinol or dopa-
mine levels after banana ingestion, the levels were not 
changed in the striatum or NAc (Lee et al. 2010). It is 
well recognised that most catecholamines in the plasma 
are not incorporated into the central nervous system 
due to their inability to cross the blood–brain barrier. 
The salsolinol detected in the brain is likely derived 
from in situ synthesis (Origitano et al. 1981), but some 
authors argue such a hypothesis (Sjöquist & Magnu-
son 1980; Song et al. 2006). However, it was found that 
N-methylsalsolinol and N-methyl-norsalsolinol pen-
etrated from the periphery into the brain (Lorenc-Koci 
et al. 2008; Thumen et al. 2002). Although no studies 
have demonstrated a mechanism by which salsolinol 
might cross the blood-brain barrier, a sodium-indepen-
dent organic cation transporter has been recognised as 
a possible active transporter of salsolinol (Taubert et 
al. 2007). Several authors have also reported that sys-
temically administered salsolinol is capable of altering 
behaviour (Antkiewicz-Michaluk et al. 2000a; Matsu-
zawa et al. 2000; Vetulani et al. 2001), which indirectly 
suggests that it could cross the blood-brain barrier. In 
our experiment, we did not observe any behavioural 
changes in the animals, and we did not observe any 
changes in CRF levels between experimental groups. 
However, we did observe an increase in the percentage 
of mean residual solid food in the stomach, suggesting 
reduced gastric emptying, which remains in agreement 
with the findings of Banach et al. (2005, 2006). They 
reported that intraperitoneally administered salsolinol 
altered gastric motility and might have a direct effect 
on intramuscular interstitial cells of Cajal and neuronal 
pathways of reflex mechanisms located within the gas-
trointestinal intestinal wall or the vagal nerves (Banach 
et al. 2005, 2006). We also reported a decrease in large 
intestine transit and a marked decrease in the water 
content of faecal matter (Kurnik et al. 2015). Abnormal 
gastrointestinal motility and absorption might contrib-
ute to slower body weight gain and adipose tissue accu-
mulation in salsolinol-treated rats.
Enteric reflexes are initiated by stimulation of sen-
sory nerve endings located in the mucosa or within the 
muscle layers projecting from nerve cell bodies mainly 
in the myenteric plexus but also in the circular muscle 
and submucosal plexus (Kunze & Furness 1999). 
Those reflex circuits are located within the enteric 
nervous system, which is composed of small ganglia 
residing along the gastrointestinal tract. The ganglia 
contain neurons and glial cells and in many aspects 
are similar in structure to the central nervous system, 
except for the lack of connective tissue elements and 
blood-enteric nervous system barrier (Gershon 2005). 
In addition to the classical neurotransmitters, ace-
tylcholine and adrenaline/noradrenaline, nerve cells 
can express a number of other putative transmitters. 
Dopamine is indeed an important mediator of gas-
trointestinal secretion, absorption, and motility and is 
the predominant catecholamine neurotransmitter of 
the central and peripheral nervous systems. Therefore, 
there is a chance that salsolinol might affect enteric 
dopaminergic neurotransmission. Unfortunately, 
characterization of dopamine and dopamine receptors 
in the gastrointestinal tract is challenging for several 
reasons. First, dopamine can produce inhibitory and 
excitatory effects on gastrointestinal motility. Second, 
localization of dopamine receptors has been hampered 
by the identification of dopamine receptors in loca-
tions that appear to be species specific. Third, studies 
Tab. 1. Dosage and route of administration of salsolinol in experimental studies.
Dosage
Route of 
administration
Initial body weight 
of male Wistar rats
Authors
100 mg/kg daily in 0.9% NaCI (single dose or 14 days) i.p. 220–240 g Wąsik et al. 2015
200 mg/kg in total – osmotic mini-pumps –14 or 28 days i.p. ~235 g Kurnik et al. 2012, 2013, 2015
0.03, 0.3,1 or 3 μmol in artificial cerebrospinal fluid pVTA 350–400 g Deehan et al. 2013
50 mg/kg daily (21 days) i.p. 180–220 g Gil et al. 2011
30 pmol in artificial cerebrospinal fluid pVTA ~300 g Hipólito et al. 2011
0.3,3, 30, 300 and 3,000 pmol in artificial cerebrospinal fluid pVTA 300–320 g Hipólito et al. 2010
0.1,5 and 25 μmol in artificial cerebrospinal fluid NAc 300–320 g Hipólito et al. 2009
0.03, 0.1,0.3,1 or 3 μmol in artificial cerebrospinal fluid 
(multiple self-infusions)
pVTA or aVTA 250–320 g Rodd et al. 2008
50 mg/kg daily (21 days) i.p. ~200 g Banach et al. 2005, 2006
10 mg/kg in 0.9% NaCI (single dose) i.p. 220–250 g Vetulani et al. 2001
100 mg/kg in 0.9% NaCI (single dose) i.p. 220–240 g Antkiewicz-Michaluk et al. 2000a
100 mg/kg daily in 0.9% NaCI (single dose or 18 days) i.p. 190–220 g Antkiewicz-Michaluk et al. 2000b
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of dopamine in the gastrointestinal tract motility have 
often used pharmacologic amounts of this agonist, and 
interpretation of results has been confounded by the 
ability of dopamine to activate adrenergic receptors at 
high doses (Kurnik et al. 2015; Li at al. 2004). 
However, the gastrointestinal tract is not only under 
neural but also under extensive endocrine control. 
Chemosensing of gut luminal contents plays a criti-
cal role in the control of functions, such as digestion, 
pancreatic secretion, food intake and metabolic regu-
lation. Glucose-dependent insulinotropic polypeptide 
and glucagon-like peptide-1 are peptide hormones 
released from the gastrointestinal tract into circulation 
in response to glucose absorption. GLP-1 stimulates 
insulin secretion, increases β-cell mass, inhibits gluca-
gon secretion and delays gastric emptying. GIP stimu-
lates insulin secretion when glucose levels are elevated 
and decreases glucagon-stimulated hepatic glucose 
production. Dietary lipid is also a strong stimulant for 
GIP secretion. GIP is considered to increase the volume 
of adipose tissue by two major pathways: directly, by 
binding to GIP receptors located on adipocytes, and 
indirectly, by accelerating fat deposition and expansion 
of fat depots by increasing insulin secretion. There are 
both acute mechanisms of GIP secretion in response to 
a single administration of fat and chronic mechanisms 
for hyperproduction of GIP under high-fat feeding 
(Yamane et al. 2016). Interestingly, although prolonged 
salsolinol treatment increased postprandial GIP levels, 
the effect was not associated with increased levels of 
adipose tissue weight in our experiment. Conversely, 
postprandial GPL-1 levels were decreased after salsoli-
nol treatment, especially after two weeks (higher daily 
dose), which was associated with increased residual 
solid food in the stomachs and an increased postpran-
dial LDL to HDL ratio. 
Peripheral signals from the gut and adipose tissue 
constitute feedback mechanisms allowing for the 
maintenance of a steady body weight, despite daily 
variations in energy expenditure and nutrient intake 
(Sam et al. 2012). Over the long term, white fat mass 
reflects the net balance between energy expenditure 
and energy intake. Adipose tissue is innervated mainly 
by sympathetic fibres. The neurotransmitter involved 
is norepinephrine, which binds to different noradren-
ergic-receptor subtypes depending on the fat pad and 
the species. The role of this afferent system is still not 
well understood, but it could be very important in the 
overall regulation of energy balance in the body. Cat-
echolamines are the main hormones involved in the 
control of lipolysis (Pénicaud et al. 2000). It was postu-
lated that salsolinol might affect plasma catecholamine 
levels by interfering with epinephrine and norepi-
nephrine release from their terminal sites (Bodnár et 
al. 2004). Thus, we hypothesised that salsolinol might 
indirectly exert lypolitic effects, which is reflected by 
lowered epididymal fat pad weight over the total food 
intake ratio (Aleksandrovych et al. 2016).
Salsolinol might influence regulatory mechanisms 
associated with body weight and fat accumulation 
through neurohormonal pathways. Further studies are 
still needed to address these complex issues.
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